Cataract Surgery in the Glaucoma Patient
Cataract Surgery in the Glaucoma Patient
Preface

Cataract surgery is one of the most frequently performed procedures in the United States, and cataracts are a leading cause of visual impairment in the world. Glaucoma is also a very common eye disease with an expected 3.3 million Americans afflicted with primary open angle glaucoma by 2020. It is also a leading cause of irreversible blindness worldwide. The coexistence of these two diseases is not uncommon, and how a cataract is approached can have an impact on the glaucoma status of a patient. After all, cataracts are rarely associated with permanent blindness as is glaucoma. Managing cataracts to the best advantage of the glaucoma should result in the best long-term visual outcomes for our patients with both diseases.

While detailed instruction on cataract surgery is reviewed in other texts, this book serves to focus on the management of cataract in the setting of glaucoma, using an evidence-based medicine approach. It is hoped to serve as a wonderful resource for ophthalmologists, residents, and glaucoma fellows.

Charlottesville, VA

Sandra M. Johnson, MD
I would like to acknowledge all the contributors of this book without whom it would not be published. The experience of our mentors and the contributors to our references, cited and uncited, helped provide us with our current insights. In addition, I thank the photographers who assisted the authors including those from Dartmouth Hitchcock Medical Center (Tom Monego and Pat Saine), Medical College of Georgia (Mike Stanley), and University of Virginia (Alan Lyon, Jared Watson, and Lloyd Situkali).

Sandra M. Johnson
# Contents

## Part I  Cataract Surgery

1. **Approach to Cataract Surgery in Glaucoma Patients**
   Graham A. Lee and Ivan Goldberg

2. **Anesthesia**
   Marlene R. Moster and Augusto Azuara-Blanco

3. **Management of the Small Pupil**
   Cynthia Mattox

4. **Small Incision Cataract Surgery and Glaucoma**

5. **Elevated Intraocular Pressure After Cataract Surgery**
   Parag A. Gokhale and Emory Patterson

## Part II  Combined Surgery

6. **Combined Cataract and Trabeculectomy Surgery**
   Sandra M. Johnson

   Rengaraj Venkatesh, Rengappa Ramakrishnan, Ramasamy Krishnadas, Parthasarathy Sathyan, and Alan L. Robin

8. **Antimetabolite-Augmented Trabeculectomy Combined with Cataract Extraction for the Treatment of Cataract and Glaucoma**
   Sumit Dhingra and Peng Tee Khaw

9. **Early Postoperative Bleb Maintenance**
   Robert T. Chang and Donald L. Budenz

10. **Laser Suture Lysis and Releasable Sutures**
    Anastasios Costarides and Prathima Neerukonda

11. **Cataract Surgery Combined with Glaucoma Drainage Devices**
    Ramesh S. Ayyala and Brian J. Mikulla

12. **Choroidal Detachment Following Glaucoma Surgery**
    Diego G. Espinosa-Heidmann
| Contents |
|-----------------------------|---|
| 13 Cataract Extraction Combined with Endoscopic Cyclophotocoagulation | 129 |
| Steven D. Vold |
| 14 Approach to Cataract Extraction Combined with New Glaucoma Devices | 135 |
| Diamond Y. Tam and Iqbal Ike K. Ahmed |
| Part III Glaucoma Conditions | 159 |
| 15 Cataract Surgery in Patients with Exfoliation Syndrome | 161 |
| Anastasios G.P. Konstas, Nikolaos G. Ziakas, Miguel A. Teus, Dimitrios G. Mikropoulos, and Vassilios P. Kozobolis |
| 16 Cataract Surgery in the Presence of a Functioning Trabeculectomy Bleb | 177 |
| Hylton R. Mayer and James C. Tsai |
| 17 Cataract Extraction in Eyes with Prior GDD Implantation | 187 |
| Ramesh Ayyala and Brian Mikulla |
| 18 Cataract Surgery in the Primary Angle-Closure Patient | 189 |
| Jimmy S.M. Lai |
| 19 Nanophthalmos | 197 |
| Carlos Gustavo Vasconcelos de Moraes and Remo Susanna Jr. |
| 20 Cataract Induced Glaucoma: Phacolytic/Phacomorphic | 207 |
| Sandra M. Johnson |
| 21 Glaucoma Related to Pseudophakia | 213 |
| Junping Li and Jason Much |
| 22 Cataract and Glaucoma in Retinopathy of Prematurity | 221 |
| Anthony J. Anfuso and M. Edward Wilson |
| 23 Cataract Surgery in the Hypotonous Eye | 227 |
| Devon Ghodasra and Sandra M. Johnson |
| Appendix: Index of Major Figures and Tables | 233 |
| Index | 239 |
Contributors

Iqbal Ike K. Ahmed, MD, FRCSC  Department of Ophthalmology, University of Toronto, Toronto, ONT, Canada, ikeahmed@mac.com

Anthony J. Anfuso, MD  University of West Virginia, Morgantown, WV, USA, tony.anfuso@gmail.com

Ramesh S. Ayyala, MD, FRCS, FRCOphth  Department of Ophthalmology, Tulane University School of Medicine, New Orleans, LA, USA, rayyala@tulane.edu

Augusto Azuara-Blanco, MD, PhD, FRCS(Ed)  Department of Ophthalmology, The Eye Clinic, University of Aberdeen, Foresterhill, Aberdeen, Scotland, aazblanco@aol.com

Donald L. Budenz, MD, MPH  Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL, USA, dbudenz@med.miami.edu

Robert T. Chang, MD  Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL, USA, viroptic@yahoo.com

Anastasios Costarides, MD, PhD  Emory University School of Medicine, Emory Eye Center, Atlanta, GA, USA, acostar@emory.edu

Carlos Gustavo Vasconcelos de Moraes, M.D.  Department of Ophthalmology, Glaucoma Associates of New York, New York Eye and Ear Infirmary, New York, NY, USA, gustavousp@gmail.com

Sumit Dhingra, MBCh, MA, MRCOphth  Department of Ocular Repair and Regeneration BiologyNIHR Biomedical Research Centre, UCL Institute of Ophthalmology and Moorfields Eye Hospital, London, UK, drsumitdhingra@gmail.com

Diego G. Espinosa-Heidmann, MD  Duke University Eye Center, Durham, NC, USA, diego.espinosa-heidmann@duke.edu

Devon Ghodasra, BS  Medical College of Georgia, School of Medicine, Augusta, GA, USA, devonghodasra@gmail.com

Parag A. Gokhale, MD  Department of Ophthalmology, Virginia Mason Medical Center, Seattle, WA, USA, ophpag@vmmc.org

Ivan Goldberg, MBBS, FRANZCO, FRACS  Department of Ophthalmology, Sydney Eye Hospital, University of Sydney, Sydney, NSW, Australia, eyegoldberg@gmail.com

Sandra M. Johnson  Department of Ophthalmology, Glaucoma Service, University of Virginia School of Medicine, Charlottesville, VA, USA, catglaubk@gmail.com

Peng Tee Khaw, PhD, FRCP, FRCS, FRCOphth, FIBiol, FRCPath, FmedSci  Department of Ocular Repair and Regeneration BiologyNIHR Biomedical Research Centre, UCL Institute of Ophthalmology and Moorfields Eye Hospital, London, UK, p.khaw@ucl.ac.uk
Anastasios G.P. Konstas, MD, PhD 1st University Department of Ophthalmology, Head of the Glaucoma Unit, AHEPA Hospital, Thessaloniki, Greece, konstas@med.auth.gr

Vassilios P. Kozobolis, MD, PhD Department of Ophthalmology, University Hospital of Alexandroupolis, Medical School, Dragana, Alexandroupolis, Greece, vkozobolis@yahoo.gr

Ramasamy Krishnadas, DO, DNB Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Madurai, TN, India, krishnadas@aravind.org

Jimmy S.M. Lai, FRCSOphth, FRCEd, M.Med (Ophthalmology), M.D., L.L.B. Queen Mary Hospital, Eye Institute and Research Center for Heart Brain and Healthy Ageing, The University of Hong Kong, Cyberport, Hong Kong, China, laism@hku.hk

Graham A. Lee, MD, MBBS, FRANZCO Department of Ophthalmology, Royal Brisbane Hospital, Brisbane, QLD, Australia, eye@cityeye.com.au

Junping Li, MD, PhD Clinical Ophthalmology, University of Virginia, Chief of Ophthalmology, Salem Veterans Affairs Medical Center, Salem, VA, USA, junping.li2@va.gov

Richard L. Lindstrom, MD Department of Ophthalmology, University of Minnesota, Minnesota Eye Consultants, PA, Bloomington, MN, USA, rllindstrom@mneye.com

Cynthia Mattox, MD Department of Ophthalmology, New England Eye Center, Tufts University School of Medicine, Boston, MA, USA, cmattox@tuftsmedicalcenter.org

Hylton R. Mayer, MD Department of Ophthalmology, Yale University School of Medicine, New Haven, CT, USA, hylton.mayer@yale.edu

Dimitrios G. Mikropoulos, MD AHEPA Hospital, Thessaloniki, Greece, mikropou@med.auth.gr

Brian J. Mikulla, BS, MBA Department of Ophthalmology, Tulane University School of Medicine, New Orleans, LA, USA, bmikulla@tulane.edu

Marlene R. Moster, MD Department of Ophthalmology, Thomas Jefferson University Hospital, Philadelphia, PA, USA, marlenemoster@aol.com

Jason Much, MD Department of Ophthalmology, University of Virginia, Charlottesville, VA, USA, jwm7e@virginia.edu

Prathima Neerukonda, MD Department of Ophthalmology, Emory University, Atlanta, GA, USA, prathima77@gmail.com

Emory Patterson, MD Department of Ophthalmology, Medical College of Georgia, Augusta, GA, USA, epatterson@mcg.edu

Brooks J. Poley, MD Department of Ophthalmology, Volunteers in Medicine Clinic, Hilton Head Island, SC, USA, scbrooks@hargray.com

Rengappa Ramakrishnan, MD Department of Glaucoma, Aravind Eye Hospital, Tirunelveli, TN, India, drrk@tv1.aravind.org

Alan L. Robin, MD University of Maryland, Baltimore, MD, USA; Johns Hopkins University, Baltimore, MD, USA; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA, arobin@glaucomaexpert.com

Thomas W. Samuelson, MD Department of Ophthalmology, University of Minnesota, Phillips Eye Institute, Minneapolis, MN, USA, twsamuelson@mneye.com

Parthasarathy Sathyan, Dip.N.B. Department of Glaucoma, Aravind Eye Hospital, Peelamedu, Coimbatore, TN, India, dr.sathyan.p@gmail.com
Richard R. Schulze Jr., M. Phil. (Oxon), MD  Schulze Eye Center, Savannah, GA, USA, richardschulze@comcast.net

Remo Susanna Jr., MD  Department of Ophthalmology, University of São Paulo, São Paulo, Brazil, rsussana@terra.com.br

Diamond Y. Tam, MD  Department of Ophthalmology, University of Toronto, Toronto, ONT, Canada, diamondtam@gmail.com

Miguel A. Teus, MD, PhD  Department of Ophthalmology, Hospital Universitario “Príncipe de Asturias”, Universidad de Alcalá, Madrid, Spain, mteus@teleline.es

James C. Tsai, MD, FACS  Department of Ophthalmology & Visual Science, Department of Ophthalmology, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA, james.tsai@yale.edu

Rengaraj Venkatesh, MD  Department of Glaucoma, Aravind Eye Hospital, Thavalakuppam, Pondicherry, India, venkatesh@pondy.aravind.org

Steven D. Vold, MD  Boozman-Hof Regional Eye Clinic, P.A., Rogers, AR, USA, svold@cox.net

M. Edward Wilson Jr., MD  Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA, wilsonme@musc.edu

Nikolaos G. Ziakas, MD, PhD  1st University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece, nikolasziakas@yahoo.gr
Part I
Cataract Surgery
Chapter 1

Approach to Cataract Surgery in Glaucoma Patients

Graham A. Lee and Ivan Goldberg

Introduction

As both glaucoma and cataract are increasingly frequent with increasing age, glaucoma patients undergoing cataract surgery are common. These patients require a carefully planned approach to achieve not only a successful cataract extraction outcome but, more importantly, long-term control of their glaucoma.

Clinical History

Is cataract surgery necessary? Determine the degree of visual disability from the cataract versus that from the glaucoma; for the patient, it is the summed visual disability that affects him or her. To have realistic expectations of the potential visual benefits from surgery, patients need to understand the difference. Unless visual loss from glaucoma in the two eyes overlaps, the irreversible glaucoma damage may not be obvious to the patient. Cataract-induced visual loss presents as progressive reduction in visual acuity and in loss of fine detail and contrast (especially in low light), and glare; if allowed to progress, this may threaten a patient’s ability to drive and his or her ambulatory vision. In patients with both glaucomatous and cataractous loss, this distinction may not be clear: Glaucoma can manifest as paracentral scotomas, while cortical cataract can present as peripheral loss.

Preoperative Assessment

Glaucoma patients require the same careful preoperative examination as all cataract patients. Secondary glaucomas present specific challenges during cataract surgery; preoperative surgical planning minimizes risks of complications.

Cornea

In well-controlled glaucoma, the cornea in most patients is normal for their age. Epithelial and stromal edema (e.g., with high intraocular pressure [IOP], bullous keratopathy, and the iridocorneal endothelial [ICE] syndrome) interferes with visualization of intraocular structures (Figs. 1.1 and 1.2). Keratic precipitates may indicate previous uveitis (Fig. 1.3). Moderate endothelial loss of around 7% has been observed following trabeculectomy compared with a loss of 2.6% following deep sclerectomy. More endothelial loss occurs with two-site phacotrabeculectomy compared with one-site. This may influence choice of procedure in already gastrectomized eyes.
compromised corneas, but the degree of IOP lowering needed for a particular patient is more critical.

**Gonioscopy**

Vital in all patients, gonioscopic assessment of the angle is especially important in those with glaucoma. If less than 2.4 mm, anterior chamber depth is a significant risk factor for angle closure. Occludable and partially closed angles often reopen following cataract removal (Fig. 1.4a, b); however, there may be persistent peripheral anterior synechial closure (Fig. 1.5). Intermittent iridotrabecular contact might explain outflow damage despite an apparently open angle. Trabecular meshwork pigment with radial transillumination defects indicates pigment dispersion (Fig. 1.6a, b). Pseudoexfoliative (PXF) material on the anterior lens capsule, iris, and meshwork indicates an increased risk of zonular and capsular weakness, and of lens dislocation (Fig. 1.7; see also Chapter 15).

**Optic Nerve**

The neuroretinal rim is the key to diagnose glaucoma and to stage damage. Visual field loss should correspond to optic...
nerve rim thinning and nerve fiber layer defects. Without such correlation, suspect non-glaucomatous causes. Dense cataract can make disc assessment difficult or impossible. While advanced damage suggests a poorer visual prognosis following cataract surgery, removal of a dense cataract might improve both vision and IOP control (see Chapter 3). Look for shunt vessels (previous branch or central retinal vein occlusions) (Fig. 1.8), disc hemorrhages (increased risk of glaucoma progression) (Fig. 1.9), neovascularization, and disc drusen.

Silicone Oil

Silicone oil retinal tamponade following complicated vitreoretinal surgery may precipitate posterior subcapsular lens opacities and/or secondary glaucoma. Biometry in the presence of silicone oil is altered; Murray et al.\(^5\) reported a mean ratio of true axial length to measured axial length of 0.71 (Fig. 1.10). Calculated intraocular lens (IOL) power depends on whether the oil is to be retained or removed at the time of cataract surgery. Preserving the integrity of the posterior capsule is important to keep oil from entering the anterior segment; this reduces the probability of silicone oil-induced IOP increases and potential silicone oil keratopathy (Fig. 1.11).

Investigations

Field Analysis

Mean deviation (MD) levels in standard automated perimetry indicate severity of visual loss from both glaucoma and cataract. Pattern standard deviation (PSD) or its equivalent reduces the effect of overall field depression from a uniform cataract (Fig. 1.12a, b). Visual field changes after cataract extraction in patients with advanced field loss\(^6\) showed mean values for MD and PSD of –13.2 and 6.4 dB before and –11.9 and 6.8 dB after cataract surgery ($P \leq 0.001$ for all comparisons). Mean ($\pm$ SD) number of abnormal points on pattern deviation plot was $26.7 \pm 9.4$ and $27.5 \pm 9.0$ before and after cataract surgery, respectively ($P = 0.02$). Scotoma depth index did not change after cataract extraction (–19.3 versus –19.2 dB, $P = 0.90$). Cataract extraction generally improved the visual field; this was most marked in eyes with less advanced glaucomatous damage. Enlargement of scotomas was statistically significant, but was not clinically

Fig. 1.5 Gonioscopic view showing peripheral anterior synchiae following cataract extraction

Fig. 1.6 (a) Retroillumination of the iris demonstrating transillumination defects in pigment dispersion syndrome. (b) Gonioscopic view of increased pigmentation of the posterior trabecular meshwork in pigment dispersion syndrome
meaningful. No improvement of sensitivity was observed in the deepest part of the scotomas. In a subset of the Collaborative Initial Glaucoma Treatment Trial, visual field testing before and after cataract extraction showed an improved MD but a worse PSD. Other studies have found improvement of the MD with no change in mean PSD on SITA perimetry. Cai et al. showed the amplitude of the AccuMap (objective multifocal visual evoked potential perimetry) was increased after cataract surgery (382.6 nV ± 146.7 nV versus 308.0 nV ± 96.6 nV; \( P < 0.01 \)). The AccuMap severity index (ASI) was decreased following lens removal (48.6 ± 42.4 versus 90.0 ± 54.8, \( P < 0.001 \); \( P < 0.001 \)).

Focal lens opacities or cortical changes may simulate glaucomatous patterns of field loss, making it more difficult to separate the effects of the two pathologies. Advanced age-related cataracts may cause apparent false-positive responses with screening frequency doubling perimetry; even mild posterior subcapsular opacities may yield false-positive errors.

**Ultrasonic Biometry**

A-scan biometry measures anterior chamber depth and axial lengths. In angle closure, by removing a cataractous lens with a thickness of more than 4.5 mm and replacing it with a 1-mm-thick intraocular lens (IOL), cataract surgery
Fig. 1.11 Silicone oil droplets in anterior chamber of aphakic eye
deeplens the anterior chamber and opens the angle (Fig. 1.13a, b). In eyes with shallow anterior chambers, the IOL position is usually more posterior than was the crystalline lens; an increase of 0.5 diopters to the calculated IOL power will be closer to emmetropia. A shallow anterior chamber presents an intraoperative challenge by increasing the risk of trauma to the corneal endothelium and iris. Myopically shifted prediction of refractive error is significantly more frequent following posterior chamber intraocular lens implantation with phacotrabeculectomy compared with phacoemulsification, even when surgery was uncomplicated and performed by the same surgeon.11 Another study comparing refractive outcome from cataract surgery after successful trabeculectomy to cataract surgery only found no significant difference from the predicted refraction.12 Combined cataract surgery and trabeculectomy with mitomycin C tends to shorten the axial length and induces a corneal astigmatism and increased mean keratometry.13 Despite this alteration of the axial length and corneal curvature, the refractive outcome after a combined operation did not differ significantly from the predicted refraction. At present there is insufficient evidence to make firm recommendations as to the use of multifocal lenses in patients with glaucoma.14

Specular Microscopy/Pachymetry
Look for corneal endothelial compromise; expect it in the ICE syndrome or after penetrating keratoplasty. If the cell count is less than 500 viable cells/square millimeter and/or

Fig. 1.12 (a) Humphrey field analysis (Central 24-2) demonstrating glaucomatous field loss in the presence of dense nuclear sclerosis. (b) Humphrey field analysis (Central 24-2) demonstrating improvement in MD and to a lesser extent the PSD following cataract surgery
the central corneal thickness is greater than 640 μm, there is a significant risk of corneal decompensation post cataract surgery. Combined corneal grafting and cataract removal is an option.

Imaging of the Nerve Fiber Layer

The thickness of the nerve fiber layer is a measure of optic nerve structural integrity. While it complements the clinical assessment of the neuroretinal rim, it may be useful in anomalous discs and when cup:disc ratio is not assessable (Fig. 1.14a, b). If imaging demonstrates good preservation of the nerve fiber layer, then visual improvement following cataract surgery is more likely. Dense media opacities interfere with scan quality and thus measurement reliability. Savini et al. reported that cataract density influenced retinal nerve fiber layer (RNFL) thickness, as measured by optical coherence tomography (OCT) (Carl Zeiss Meditec, Dublin, CA). Postoperative measurements were higher than preoperative measurements in all quadrants (temporal \( P = 0.011 \); superior \( P = 0.0098 \); nasal \( P < 0.0001 \); inferior \( P = 0.0081 \)) and in 360° averages (\( P < 0.0001 \)). More advanced lens opacities correlated with a higher apparent decrease in RNFL thickness \( (r = 0.4071, P = 0.0434) \). While pupil size only marginally affected RNFL measurements performed by Stratus OCT, the presence and degree of cataract seemed to be significant. Consider this when using OCT to help diagnose glaucoma and other neuro-ophthalmologic disorders affecting the RNFL in the presence of a cataract.16

Consent

Patients undergoing cataract surgery expect a good visual outcome. Glaucoma patients with vision compromised by optic nerve damage that will not be improved by cataract removal need to be realistic in their expectations: their surgery is NOT necessarily the same as that performed for their friends and relatives. The consent process needs to address this carefully and unambiguously so that the doctor and the patient have aligned hopes and expectations.

“Snuff-out” syndrome is the loss of the remaining central visual field during or following any intraocular surgery. It is usually irreversible. Retro- or peribulbar anesthetic injection

Visante/Pentacam/Orb Scan

Various technologies image the anterior segment in detail. These are particularly useful in patients with crowded anterior segments (Figs. 1.15a, b and 1.16a, b). When planning anterior segment surgery in complex eyes, such technology can provide guidance. Dawczynski et al. studied the effect of phacoemulsification on the anterior chamber depth (ACD) and angle (ACA) in primary open angle glaucoma (POAG) and angle-closure glaucoma (ACG) compared with normals. After cataract extraction, ACD and ACA increased significantly in the ACG group (3.1 ± 0.4 mm versus 1.8 ± 0.2 mm, \( P < 0.005 \); and 32.3° ± 7.7° versus 16.0° ± 4.7°, \( P < 0.005 \)). In the POAG and control groups, ACD and ACA also increased postoperatively, but not as much as in the ACG group.

Fig. 1.13  (a) Narrowing of the anterior chamber pre-cataract surgery. (b) Widening of the anterior chamber post-cataract surgery

G.A. Lee and I. Goldberg
with a Honan’s balloon or a similar device can raise IOP to over 50 mmHg.\textsuperscript{18} Topical anesthesia may be the preferred technique to try to avoid excess pressure on the globe (see Chapter 2). Eyes with absolute splitting of fixation (<0 sensitivity, 1° from fixation on perimetric testing) are more at risk.\textsuperscript{19}
The aims of surgery need to be clearly stated. In angle-closure patients where cataract removal aims to reopen the angle, the corrected vision may still be good, with minimal lens opacities. Vision is less likely to be improved but the aim is to improve IOP control, and to protect the angle structures from further damage (see Chapter 18). Often these patients are hyperopic, with the surgery able to correct the refractive error. Cataract removal and IOL insertion in the other eye might be needed to correct anisometropia.

Preoperative Preparation for Cataract Surgery in the Glaucoma Patient

Most glaucoma patients instill one or more medications prior to cataract surgery. Commonest are the prostaglandin analogues (latanoprost, travoprost, or bimatoprost). This medication class, prior to and in the early postoperative phase, has been associated with cystoid macular edema. The literature offers conflicting advice whether to withdraw a drug of this type. In advanced glaucomatous optic nerve atrophy where IOP fluctuation could result in visually significant compromise, glaucoma medications should be continued. In earlier stages of glaucoma when the IOP control is less critical, ceasing the glaucoma medications postoperatively provides an opportunity to assess the degree of IOP lowering from the cataract surgery alone, with the potential to reduce the number of medications and to avoid the increased risk of cystoid macula edema (see Chapter 4). A reverse therapeutic trial postoperatively may permit controlled cessation of one medication at a time. Chronic use of pilocarpine results in a small pupil that poorly dilates; previous cessation may make no difference. Pupil stretching or expanders are often required and should be anticipated (see Chapter 3).

Especially in advanced glaucoma, IOP fluctuations might critically destroy surviving nerve fibers. Anticipate and
manage them: a history of high IOP is a strong risk factor. For example, it has been shown that IOP spikes greater than 30 mmHg in the first 24 h might be prevented by timolol maleate 0.5% at the end of the cataract procedure.

**Preoperative Peripheral Iridotomy**

Angle-closure patients are at risk of pupil block if dilated. Peripheral iridotomy might be indicated to allow safe fundal examination preoperatively and if there is a delay in performing the surgery.

**Anticoagulants**

Patients on anticoagulants (including aspirin, non-steroidal anti-inflammatory drugs, warfarin, and clopidogrel) are at increased risk of hemorrhage. In some patients these medications can be ceased safely 10 days pre-surgery (4 days for warfarin) and restarted afterward. When it is critical for the patient to remain on the anticoagulant, consult with other doctors caring for the patient, and consider switching to heparin (e.g., subcutaneous enoxaparin) until the day of surgery. If anticoagulants cannot be ceased, a topical approach is preferable to avoid the bleeding risks of injection. Patients who are unsuitable for topical surgery may need a general anesthetic. Systemic anticoagulation has also been associated with the risk of suprachoroidal hemorrhage.

**Steroids**

Topical and even oral steroids used preoperatively might help patients at risk of heightened inflammation. In uveitic glaucoma patients, quiet the eye as much and for as long as possible prior to surgery. With adequate inflammation suppression, phacotrabeculectomy with mitomycin C can be an effective and safe therapeutic option for secondary cataract and glaucoma in uveitic eyes. Lower surgical success rates might follow later resurgence of inflammation. A combined cataract surgery with glaucoma drainage device is an alternative to phacotrabeculectomy. See Chapter 11.

**Approach to Surgery**

Glaucoma patients can present with visual loss from cataract and cataract patients can present with glaucoma. The aims of surgery in each situation need to be defined clearly, with the doctor and patient reaching a common understanding. For most patients the perceived goal is often improved vision. This may not be achievable. It is for the doctor to communicate realistic aims, which include the following:

1. Improvement of vision if cataract is a significant cause of loss—the greater the loss from glaucoma, the less certain is such improvement.
2. Maintenance of vision if further loss from glaucoma is threatened.
3. Control of IOP if the cataract is involved in the mechanisms raising IOP or if a filtration operation is being performed to improve IOP control, or to allow cessation of medications with the concurrent existence of cataract to be managed.

**Cataract Only**

If visual field loss has been stabilized by adequate IOP control, perform cataract surgery when reduction in visual function interferes with daily living. Consider cataract surgery alone if glaucoma damage is relatively mild, when there are no other relevant ocular pathologies and visual improvement is likely. Provided IOP control is maintained postoperatively, no further procedure should be necessary.

In other patients with mild-to-moderate elevation of IOP, cataract extraction alone may lower IOP adequately. Mathalone et al. evaluated long-term IOP control after sutureless clear corneal phacoemulsification in eyes with medically controlled glaucoma. At 12 months, mean IOP decrease was 1.5 mmHg ± 4.4 (SD), and 1.9 ± 4.9 mmHg at 24 months. The mean decrease in the number of medications was 0.53 ± 0.86 (P = 0.4) at 12 months and 0.38 ± 0.9 (P = 0.4) at 24 months. Phacoemulsification in non-glaucomatous pseudoexfoliation syndrome patients significantly reduced IOP by about 3.5 mmHg at 1 year. Pseudoexfoliative glaucoma patients demonstrated more IOP reduction than did normals and primary open angle glaucoma patients undergoing phacoemulsification. In patients with primary angle-closure, both IOP and the need for glaucoma drugs could be reduced by phacoemulsification alone. IOP fell from a mean preoperative level of 19.7 ± 6.1 mmHg (range 11–40 mmHg) to 15.5 ± 3.9 mmHg (range 9–26 mmHg) at final follow-up (P = 0.022) (paired t-test), while the number of glaucoma agents fell from a mean 1.91 ± 0.77 (range 1–3) to 0.52 ± 0.87 (range 0–3) at final follow-up (P < 0.001; paired t-test). Early phacoemulsification appeared to be more effective to prevent an IOP rise than laser peripheral iridoplasty in patients who had had an aborted episode of acute primary angle closure. Phacoemulsification reduced
the mean number of medications and consistently increased Shaffer gonioscopy grading. The effect of peripheral laser iridotomy compared with cataract surgery on the angle showed residual angle closure after iridotomy in 27 (38.6%) of 70 eyes; this was confirmed functionally by the dark room prone test and morphologically by ultrasound biomicroscopy (UBM). Eyes with IOP of ≥20 mmHg or with a glaucomatous visual field defect before iridotomy had a significantly higher prevalence of residual angle closure after iridotomy than did eyes without these findings (P < 0.05). In all the eyes with residual angle closure after iridotomy, the response to the prone test became negative after cataract surgery, with significant lowering of IOP (P < 0.01).33 Residual angle closure after iridotomy was common, especially in eyes with primary angle closure and poorly controlled IOP or glaucomatous optic neuropathy. Cataract surgery effectively resolved residual angle closure after iridotomy and lowered IOP. Using UBM, Nonaka et al. measured anterior chamber depth (ACD), angle opening distance at points 500 μm from the scleral spur (AOD500), and trabecular-ciliary process distance (TCPD).34 Correlated with one another, all parameters increased significantly after cataract surgery (P < 0.001). Cataract surgery not only eliminated pupillary block but also attenuated any anterior positioning of the ciliary processes.

In 12 consecutive patients with end-stage glaucoma who underwent cataract surgery, 6 months postoperatively, Altmeyer et al. reported35 improved mean visual acuity (from 0.3 to 0.5; P = 0.007) and decreased IOP (by 4.4 mmHg; P = 0.007); anti-glaucomatous drugs decreased in number from 1.5 preoperatively to 0.8, and mean deviation (MD) improved from −27.5 to −26.4 dB (P = 0.036). Thus patients with progressive cataract and end-stage glaucoma can benefit from cataract surgery.

**Cataract and Glaucoma Surgery**

Glucoma patients with progressive visual loss and higher than desirable IOP, despite medical and laser strategies, require drainage surgery. In the presence of a visually significant cataract, determine whether cataract or glaucoma surgery or both are needed.

If the cataract is extracted first, IOP might fall. This is particularly likely if an angle-closure mechanism is eliminated before trabecular function has been damaged.36 In open angle glaucoma patients, the reasons for reduced IOP after cataract surgery are less obvious.

Routine cataract surgery provokes subclinical inflammation. Increased flare after routine cataract surgery has been measured for up to 30 days postoperatively.37 As this implies exaggerated wound healing, to optimize trabeculectomy function, it could be better to delay drainage at least until after this period. If IOP control is poor following cataract surgery, despite maximal tolerable medication, then drainage will be needed under suboptimal conditions, increasing likely benefit from anti-metabolite augmentation and/or pre- as well as postoperative topical and even oral steroids. Luo et al. measured mean aqueous flare values of 15.12 ± 2.87, 40.24 ± 3.75, 24.33 ± 3.38, 21.18 ± 1.77, and 16.51 ± 1.70 (photon counts/ms) preoperatively and on days 1, 7, 30, and 90, respectively, after trabeculectomy (P < 0.05) compared with 6.94 ± 2.34, 26.27 ± 10.21, 13.96 ± 6.44, 9.07 ± 2.67, and 7.16 ± 1.89, respectively, after phacoemulsification (P < 0.05). Trabeculectomy disrupted the blood-aqueous barrier permanently whilst phacoemulsification affected it transiently.37

**Drainage Surgery Followed by Cataract Surgery**

In patients with uncontrolled IOP it might be urgent to perform drainage prior to cataract surgery. When IOP is high and/or there is advanced glucoma damage threatening fixation, there is potential for visual “snuff-out,” especially with IOP spikes. Trabeculectomy was associated with progressive cataract—predominantly the posterior subcapsular variety.38

Previously functioning drainage procedures can fail after cataract surgery, most likely by bleb exposure to induced inflammatory mediators. Approximately 50% of patients undergoing clear cornea phacoemulsification after trabeculectomy will require either further medication or further surgery to maintain target IOP.39,40 Identified risk factors for bleb failure include cataract extraction, age greater than 60 years, interval of 5 months or less between trabeculectomy and cataract extraction, use of pre-cataract extraction glucoma medications, and postoperative IOP >19 mmHg within 2 weeks.41 Cataract surgery after previously successful bleb needling revision significantly compromised bleb function.42

To reduce the potential for fibrosis, subconjunctival 5-fluorouracil (5-FU) with or without needling can be useful. Sharma et al. retrospectively evaluated the protective role of subconjunctival 5-FU on a preexisting bleb in patients with primary open angle glucoma undergoing phacoemulsification more than 12 months post-trabeculectomy. Data were collected for two groups of patients: Group 1 (22 patients) received 5-FU at the end of successful phacoemulsification, whereas group 2 (25 patients) did not. Reduced IOP control was seen in 13.6% of the patients in group 1 and in 36.4% in group 2 (P = 0.03). 5-FU seemed to protect bleb function.43 Consider it at the end of phacoemulsification in such cases. See also Chapter 16.
Table 1.1 Filtration surgeries reported combined with cataract surgery

- Trabeculectomy
- Glaucoma drainage device
- EX-PRESS mini shunt
- Viscocanulostomy
- Canaloplasty
- Non-penetrating deep sclerectomy
- Goniotomy/trabeculotomy
- Eyepass shunt

Combined Surgery

Many studies address outcomes of combined versus separate glaucoma and cataract surgery (Table 1.1). Jin et al. reviewed two-site phacotrabeculectomy in 60 eyes of 43 patients. An IOP 21 mmHg or less was achieved in 95% with or without medications; however, only 50% had an IOP of 15 mmHg or lower.44 This suggests less effective overall IOP control often achieved with trabeculectomy with mitomycin-C (phacotrabMMC).45 Mean IOP lowered from 28.2 ± 3.1 mmHg in trabMMC versus –6.15 ± 7.01 mmHg in phacotrabMMC at 2 years, $P = 0.003$; however, baseline IOP was also higher in the trabMMC group (26.1 mmHg versus 20.3 mmHg, $P < 0.0001$). TrabMMC and phacotrabMMC may be equally safe and effective in bringing IOP to within an acceptable target range over 2 years in advanced glaucoma patients at increased risk for filtering surgery failure, although trabMMC appears to be associated with greater IOP reduction.

Same-site or two-site combined surgery has been assessed with no clear superiority of either.2,45–47 The role of combined surgery is advantageous in elderly patients who are unsuitable for multiple procedures. Cotran et al. studied one-site versus two-site phacotrabeculectomy over a 3-year period.48 The mean preoperative IOP was 20.1 ± 3.8 mmHg in the one-site group and 19.5 ± 5.3 mmHg in the two-site group ($P = 0.56$) using 2.3 ± 0.9 and 2.5 ± 0.9 anti-glaucoma medications, respectively ($P = 0.27$). After 3 years, mean IOP was 12.6 ± 4.8 mmHg in the one-site group and 11.7 ± 4.0 mmHg in the two-site group ($P = 0.40$), instilling 0.3 ± 0.7 and 0.4 ± 0.9 medications, respectively ($P = 0.59$). At the end of the study, 73% of one-site eyes and 78.4% of two-site eyes had IOPs less than 18 mmHg on no anti-glaucoma medications ($P = 0.59$). Operating time was less in the one-site group ($P < 0.0001$). One-site fornix-based and two-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and in reducing the need for anti-glaucoma medications over a 3-year follow-up period. See Chapter 6.

Phacoemulsification can also be combined with a glaucoma drainage device, such as an Ahmed valve. Nasser et al. reviewed 41 eyes in 31 patients who underwent combined phacoemulsification and Ahmed valve implantation. The mean IOP lowered from 28.2 ± 3.1 to 16.8 ± 2.1, while the number of anti-glaucoma medications fell from 2.6 ± 0.66 to 1.2 ± 1.4. An IOP of <21 mmHg on no medications or on one or more medications was achieved in 56.1 and 31.7%, respectively. Five eyes (12.2%) were considered failures (IOP < 6 mmHg or > 21 mmHg).49 Other devices, such as the Eyepass glaucoma implant are under trial, but may not achieve consistent low target IOPs.50 Traverso et al. and Rivier et al. have studied a stainless steel glaucoma drainage implant (Ex-PRESS). With a subconjunctival position, conjunctival erosion and extrusion were significant problems.51,52 Positioned under a scleral trapdoor, these problems have been addressed.53 Combined phacoemulsification and ab interno trabeculectomy and endoscopic-controlled erbium:YAG-laser goniotomy require more extensive study.54,55

Deep sclerectomy with phacoemulsification may be viable if augmented with intraoperative mitomycin C. There is reduced hypotensive efficacy compared with trabeculectomy but with less chance of cystic blebs, delayed bleb leaks, and infection.56 Viscocanalostomy has also been combined with phacoemulsification.57–61 Non-penetrating glaucoma surgery may not achieve low enough IOPs, especially for more advanced glaucoma patients.62,63 Larger long-term IOP fluctuations after this type of triple procedure were associated with progressive visual field deterioration even though patients with glaucoma maintained their IOPs.64 Combined phacoemulsification and cyclophacoagulation, either transscleral or endoscopic, is an option, particularly in patients unsuitable for drainage surgery. Problems are the narrow margins for success, with significant risks of uncontrolled IOP needing additional photoacoagulation on the one hand, and of induced phthisis on the other.65,66 See Chapter 13.

Phacotrabeculectomy can be supplemented with early and repeated needle revisions with 5-FU to improve outcomes.67 In “normal pressure glaucoma,” phacoviscocanalostomy achieved 20% and 30% IOP reductions with (or without) medications in 78.5% (67.4%) and 35.5% (37.4%) of patients at 24 months, and 58.0% (44.2%) and 28.0% (26.6%) of patients at 48 months; these were better than in the cataract-extraction-only group, with only 16.0% (9.5%) and 5.7% (2.9%) at 24 months ($P < 0.001$ for each comparison, Kaplan-Meier life-table analysis with log-rank test).61 Microincision bimanual phacotrabeculectomy may be an option as incision sizes reduce in future.68
In aqueous misdirection glaucoma, a sequential three-step surgical approach has been suggested[^69]: initial vitrectomy, phacoemulsification, and definitive vitrectomy. Step 1: preliminary limited core vitrectomy to “debulk” the vitreous and soften the eye. Step 2: phacoemulsification performed in a standard manner. Step 3: residual vitrectomy, zonulohyaloidectomy, and peripheral iridectomy (if not already present) to create free communication between the posterior and anterior segments[^69].

A novel combined approach is circumferential viscodilation and tensioning of the inner wall of Schlemm’s canal (canaloplasty) to treat open angle glaucoma (OAG), combined with clear corneal phacoemulsification and posterior chamber IOL implantation.[^70] The mean preoperative baseline IOP was 24.4 ± 6.1 mmHg (SD) with a mean of 1.5 ± 1.0 medications per eye. In all eyes, the mean postoperative IOP was 13.6 ± 3.8 mmHg at 1 month, 14.2 ± 3.6 mmHg at 3 months, 13.0 ± 2.9 mmHg at 6 months, and 13.7 ± 4.4 mmHg at 12 months. Medication use dropped to a mean of 0.2 ± 0.4 per patient at 12 months. Surgical complications were reported in five eyes (9.3%): hyphaema (n = 3, 5.6%), Descemet’s tear (n = 1, 1.9%), and iris prolapse (n = 1, 1.9%). Transient IOP elevation of >30 mmHg was observed in four eyes (7.3%) 1 day postoperatively. Canaloplasty is a complex procedure requiring expensive equipment; its long-term value remains to be demonstrated.

**Summary**

A careful history, thoughtful and thorough clinical assessment with the aid of emerging technologies, planned surgical steps, and a fully informed consent process will increase the chances of a satisfactory outcome for the majority of patients. The approach to surgery and the postoperative care is just as important as the surgery itself.

**References**

Approach to Cataract Surgery in Glaucoma Patients


